Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Frequently asked questions
What sector does Cellectis S.A (CMVLF) operate in?
Cellectis S.A belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cellectis S.A (CMVLF) current stock price?
As of the latest data, Cellectis S.A stock price is $0.99, with a previous close of $0.99.
What is Cellectis S.A (CMVLF) current market capitalization?
Cellectis S.A market cap is approximately 72.15 million.
What is Cellectis S.A (CMVLF) Earnings Per Share (EPS)?
The trailing EPS is -$0.64.
What is Cellectis S.A (CMVLF) EBITDA?
Cellectis S.A EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.37 million.
Does Cellectis S.A (CMVLF) pay dividends?
No. Cellectis S.A does not pay a dividend.
What is Cellectis S.A (CMVLF) beta (volatility) score?
Cellectis S.A has a beta of 2.913, indicating very high volatility compared to the market.
